Astellas files for degarelix approval in Japan
This article was originally published in Scrip
Astellas has filed an application in Japan for the approval of the gonadotropin-releasing hormone receptor antagonist, degarelix acetate (ASP3550), for the treatment of prostate cancer.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.